carmustine + bendamustine + gemcitabine + vinorelbine + atezolizumab

This is a multi-agent combination regimen that includes carmustine, bendamustine, gemcitabine, vinorelbine (all cytotoxic chemotherapies), and atezolizumab (a monoclonal antibody checkpoint inhibitor). Each drug has independent antineoplastic mechanisms: - **Carmustine** is an alkylating agent that forms cross-links in DNA and RNA, inhibiting replication and transcription, leading to cell death[5][7]. - **Bendamustine** is a bifunctional nitrogen mustard that acts primarily as an alkylating agent (cross-linking DNA) and also has antimetabolite characteristics[1][5][9][11]. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, leading to apoptosis. - **Vinorelbine** disrupts microtubule assembly and mitosis by binding tubulin. - **Atezolizumab** is a monoclonal antibody targeting PD-L1, blocking its interaction with PD-1, and thereby activating antitumor immune responses. Such a regimen would be highly aggressive and is typically explored in early phase clinical trials for relapsed or refractory lymphomas or as salvage chemotherapy. Regimens combining subsets of these drugs, such as BEGEV (bendamustine + gemcitabine + vinorelbine), are used as salvage therapies for Hodgkin lymphoma, and atezolizumab is generally used in immuno-oncology for various tumors but not as a standard part of these cytotoxic combinations[2][4][10][12]. There is no evidence for this five-drug combination as an established regimen; it may represent an experimental or trial protocol.